Home > Healthcare > Medical Devices > Diagnostic Devices > Point of Care Infectious Disease Testing Market

Point of Care Infectious Disease Testing Market Trends

Report ID: GMI11938
Published Date: Oct 2024
Report Format: PDF

Download Free Sample

Point of Care Infectious Disease Testing Market Trends

Increased awareness about the benefits of early detection and management of infectious diseases has contributed to the growth of the POC testing market. With more education on the importance of timely diagnosis, particularly for contagious diseases, there has been a rise in demand for accessible and rapid testing solutions.
Campaigns led by governments, non-governmental organizations, and healthcare providers focus on promoting self-testing and the convenience of POC diagnostics for diseases such as HIV and influenza.
Therefore, the growing consumer interest in health monitoring, combined with an increased focus on preventative care, stimulates the adoption of POC testing. This provides immediate results and helps reduce the spread of infections.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global point-of-care infectious disease testing industry was valued at approximately USD 3.2 billion in 2023 and is estimated to grow at a 6.9% CAGR from 2024 to 2032, driven by the need for rapid diagnostic results.

The kits and reagents segment generated USD 2.5 billion in revenue in 2023 and is expected to grow significantly due to their ease of use and quick turnaround times, which are crucial in various healthcare settings.

North America's market accounted for a 46.6% revenue share in 2023 and is projected to reach USD 2.7 billion by 2032, supported by a robust healthcare system and advanced technology.

Key players in the market include Abbott Laboratories, Becton, Dickinson and Company, Biomerieux, Bio-Rad Laboratories, Cardinal Health, Chembio Diagnostics, Danaher Corporation, F. Hoffmann-La Roche, OJ-Bio, and QuidelOrtho Corporation.